This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2006 by Sheba Medical Center.
Recruitment status was:  Not yet recruiting
Sponsor:
Information provided by:
Sheba Medical Center
ClinicalTrials.gov Identifier:
NCT00339118
First received: June 19, 2006
Last updated: NA
Last verified: June 2006
History: No changes posted
June 19, 2006
June 19, 2006
Not Provided
Not Provided
  • event free survival
  • overall survival
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children
Not Provided
The purpose of the study is achieve standardization treatment of low and intermediate risk rhabdomyosarcoma patients, with an attempt to improve treatment results in high and very high risk patients by the addition of doxorubicin as induction treatment and at the maintenance phase.
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Rhabdomyosarcoma
Drug: doxorubicin, cytoxan
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • child
  • non metastatic rhabdomyosarcoma
  • adequate heart, kidney, liver function

Exclusion Criteria:

  • age over 21 years, under 6 months
  • metastatic disease
  • heart, kidney, liver disease
Sexes Eligible for Study: All
6 Months to 21 Years   (Child, Adult)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00339118
SHEBA-06-4013-IK-CTIL
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Sheba Medical Center
Not Provided
Principal Investigator: Iris Kventsel, MD Sheba Medical Center
Sheba Medical Center
June 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP